Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
EU to Weigh New Safety Data on Biogen, Eisai Alzheimer’s Drug
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Investing21h
Eli Lilly and Co DRC (LLYm)
On Friday, Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995.00, while reiterating a Buy rating on the ...